Marcus Quinkler

ORCID: 0000-0003-4028-1671
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hormonal Regulation and Hypertension
  • Adrenal and Paraganglionic Tumors
  • Adrenal Hormones and Disorders
  • Pituitary Gland Disorders and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Hormonal and reproductive studies
  • Sexual Differentiation and Disorders
  • Glioma Diagnosis and Treatment
  • Electrolyte and hormonal disorders
  • Stress Responses and Cortisol
  • Growth Hormone and Insulin-like Growth Factors
  • Estrogen and related hormone effects
  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Ion Transport and Channel Regulation
  • Birth, Development, and Health
  • Vitamin D Research Studies
  • Neuroendocrine Tumor Research Advances
  • Parathyroid Disorders and Treatments
  • Liver Disease Diagnosis and Treatment
  • Apelin-related biomedical research
  • Aldose Reductase and Taurine
  • Diet, Metabolism, and Disease
  • Blood Pressure and Hypertension Studies
  • Neuroblastoma Research and Treatments
  • Bone health and treatments

Endokrinologikum
2003-2025

Charité - Universitätsmedizin Berlin
2013-2023

Comprehensive Cancer Center Mainfranken
2023

University of Würzburg
2009-2023

Humboldt-Universität zu Berlin
2019-2022

Freie Universität Berlin
1996-2022

Eilenburger Elektrolyse - und Umwelttechnik (Germany)
2021

Pathodiagnostik Berlin
2020

Laiko General Hospital of Athens
2020

St Petersburg University
2019

Adrenocortical carcinoma is a rare cancer that has poor response to cytotoxic treatment.We randomly assigned 304 patients with advanced adrenocortical receive mitotane plus either combination of etoposide (100 mg per square meter body-surface area on days 2 4), doxorubicin (40 day 1), and cisplatin 3 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g 1 5 in cycle 1; subsequent cycles) weeks. Patients disease progression received the alternative regimen as second-line therapy. The...

10.1056/nejmoa1200966 article EN New England Journal of Medicine 2012-05-02

10.1016/s2213-8587(17)30135-3 article EN The Lancet Diabetes & Endocrinology 2017-05-31

Adrenocortical carcinoma (ACC) is a rare malignancy, and it was only in 2004 that the International Union Against Cancer (UICC) defined TNM criteria published first staging classification. However, to date, prognostic value of proposed classification has not been evaluated.The German ACC Registry comprising 492 patients searched for who were diagnosed between 1986 2007 with detailed information on primary diagnosis minimum follow-up 6 months. Patients assigned UICC tumor stage,...

10.1002/cncr.24030 article EN Cancer 2008-11-24

Adrenal crisis (AC) is a life-threatening complication of adrenal insufficiency (AI), which according to retrospective data represents significant clinical complication. Here we aimed prospectively assess incidence AC and mortality associated with in patients chronic AI.A total 423 AI (primary AI, n = 221; secondary 202) were followed up for 2 years. Baseline assessment included general questionnaire detailed written instructions on glucocorticoid dose adaptation during stress. Patients...

10.1210/jc.2014-3191 article EN The Journal of Clinical Endocrinology & Metabolism 2014-11-24

In patients who seek surgical cure of primary aldosteronism (PA), The Endocrine Society Guidelines recommend the use adrenal vein sampling (AVS), which is invasive, technically challenging, difficult to interpret, and commonly held be risky. aim this study was determine complication rate AVS ways in it performed interpreted at major referral centers. Adrenal Vein Sampling International Study an observational, retrospective, multicenter conducted centers for endocrine hypertension worldwide....

10.1210/jc.2011-2830 article EN The Journal of Clinical Endocrinology & Metabolism 2012-03-08

Adrenal crisis (AC) is a life-threatening complication of adrenal insufficiency (AI). Here, we evaluated frequency, causes and risk factors AC in patients with chronic AI.In cross-sectional study, 883 AI were contacted by mail. Five-hundred twenty-six agreed to participate received disease-specific questionnaire.Four-hundred forty-four datasets available for analysis (primary (PAI), n=254; secondary (SAI), n=190). Forty-two percent (PAI 47% SAI 35%) reported at least one crisis. Three...

10.1530/eje-09-0884 article EN European Journal of Endocrinology 2009-12-03

Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently. The aim this study was to identify markers with prognostic value for patients in clinical setting. From the German ACC registry, 319 European Network Study Adrenal Tumors stage I–III were identified. As an independent validation cohort, 250 from three countries included. Clinical, histological, and immunohistochemical correlated recurrence-free (RFS) overall survival (OS). Although univariable...

10.1210/jc.2014-3182 article EN The Journal of Clinical Endocrinology & Metabolism 2015-01-05

Primary aldosteronism is the most common form of secondary hypertension. Somatic mutations in KCNJ5 , ATP1A1 ATP2B3 and CACNA1D have been described aldosterone-producing adenomas (APAs). Our aim was to investigate prevalence somatic these genes unselected patients with APA (n=474), collected through European Network for Study Adrenal Tumors. Correlations clinical biochemical parameters were first analyzed a subset 199 from single center then replicated 2 additional centers. heterozygous...

10.1161/hypertensionaha.114.03419 article EN Hypertension 2014-05-28

Primary aldosteronism is the most common form of secondary hypertension. Mutations in KCNJ5 gene have been described recently aldosterone-producing adenomas (APAs). The aim this study was to investigate prevalence mutations unselected patients with primary and their clinical, biological molecular correlates. sequencing performed on somatic (APA, n=380) peripheral n=344; bilateral adrenal hyperplasia, n=174) DNA aldosteronism, collected through European Network for Study Adrenal Tumors....

10.1161/hypertensionaha.111.186478 article EN Hypertension 2012-01-24

In comparison with essential hypertension, primary aldosteronism (PA) is associated an increased risk of cardiovascular morbidity. To date, no data on mortality have been published. We assessed patients treated for PA within the German Conn's registry and identified factors adverse outcome in a case-control study. Patients confirmed 3 university centers Germany since 1994 were included analysis. All contacted 2009 2010 to verify life status. Subjects from population-based F3 survey...

10.1161/hypertensionaha.112.197111 article EN Hypertension 2012-07-24

Adrenal aldosterone excess is the most common cause of secondary hypertension and associated with increased cardiovascular morbidity. However, adverse metabolic risk in primary aldosteronism extends beyond hypertension, rates insulin resistance, type 2 diabetes, osteoporosis, which cannot be easily explained by excess.We performed mass spectrometry-based analysis a 24-hour urine steroid metabolome 174 newly diagnosed patients (103 unilateral adenomas, 71 bilateral adrenal hyperplasias)...

10.1172/jci.insight.93136 article EN JCI Insight 2017-04-19
Irina Bancos Angela E. Taylor Vasileios Chortis Alice Sitch Carl Jenkinson and 95 more Caroline Davidge‐Pitts Katharina Lang Stylianos Tsagarakis Magdalena Macech Anna Riester Timo Deutschbein Ivana D Pupovac Tina Kienitz Alessandro Prete Thomas Papathomas Lorna C Gilligan Cristian Bancos Giuseppe Reimondo Magalie Haissaguerre Ljiljana Marina Marianne Aardal Grytaas Ahmed Sajwani Katharina Langton Hannah E Ivison Cedric Shackleton Dana Erickson Miriam Asia Sotiria Palimeri Agnieszka Kondracka Ariadni Spyroglou Cristina L. Ronchi Bojana Simunov Danae A. Delivanis Robert P. Sutcliffe Ioanna Tsirou Tomasz Bednarczuk Martín Reincke Stephanie Burger‐Stritt Richard A. Feelders Letizia Canu Harm R. Haak Graeme Eisenhofer Michael Conall Dennedy Grethe Åstrøm Ueland Miomira Ivović Antoine Tabarin Massimo Terzolo Marcus Quinkler Darko Kaštelan Martin Faßnacht Felix Beuschlein Urszula Ambroziak Dimitra A. Vassiliadi Michael O’Reilly William F. Young Michael Biehl Jonathan J Deeks Wiebke Arlt Stephan Glöckner Richard Sinnott Anthony Stell Maria Candida Barisson Villares Fragoso Darko Kaštelan Ivana D. Pupovac Bojana Simunov Sarah Cazenave Magalie Haissaguerre Antoine Tabarin Jérôme Bertherat Rossella Libé Tina Kienitz Marcus Quinkler Katharina Langton Graeme Eisenhofer Felix Beuschlein Christina Brugger Martín Reincke Anna Riester Ariadni Spyroglou Stephanie Burger‐Stritt Timo Deutschbein Martin Faßnacht Stefanie Hahner Matthias Kroiß Cristina L. Ronchi Sotiria Palimeri Stylianos Tsagarakis Ioanna Tsirou Dimitra A. Vassiliadi Vittoria Basile Elisa Ingargiola Giuseppe Reimondo Massimo Terzolo Letizia Canu Massimo Mannelli Hester Ettaieb Harm R. Haak Thomas Kerkhofs Michael Biehl Richard A. Feelders

Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity characteristics. We aimed to validate a urine steroid metabolomics approach, using profiling as the diagnostic basis for ACC.

10.1016/s2213-8587(20)30218-7 article EN cc-by The Lancet Diabetes & Endocrinology 2020-07-23

Background: Benign adrenal tumors are commonly discovered on cross-sectional imaging. Mild autonomous cortisol secretion (MACS) is regularly diagnosed, but its effect cardiometabolic disease in affected persons ill defined. Objective: To determine burden and steroid excretion with benign without MACS. Design: Cross-sectional study. Setting: 14 endocrine secondary tertiary care centers (recruitment from 2011 to 2016). Participants: 1305 prospectively recruited tumors. Measurements: Cortisol...

10.7326/m21-1737 article EN Annals of Internal Medicine 2022-01-03

Abstract The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort mPPGLs that high mutational load, microsatellite instability and somatic copy-number alteration burden associated ATRX / TERT alterations suitable prognostic markers. Transcriptomic analysis defines the signaling networks involved acquisition competence establishes gene...

10.1038/s41467-023-36769-6 article EN cc-by Nature Communications 2023-02-28

There is mounting evidence that current replacement regimens fail to restore health-related subjective health status fully in patients with adrenal insufficiency (AI). Here we evaluated the primary and secondary AI effect of concomitant disease.In a cross-sectional study, all registered University Hospital Wuerzburg (n = 148) or German Self-Help Network 200) were contacted by mail. Underlying diagnoses comorbidities verified review medical records. Patients asked complete three validated...

10.1210/jc.2007-0685 article EN The Journal of Clinical Endocrinology & Metabolism 2007-08-08

Primary aldosteronism (PA) is associated with vascular end-organ damage.Our objective was to evaluate differences regarding comorbidities between the hypokalemic and normokalemic form of PA.This a retrospective cross-sectional study collected from six German centers (German Conn's registry) 1990 2007.Of 640 registered patients PA, 553 were analyzed.Comorbidities depending on hypokalemia or normokalemia examined.Of (61 +/- 13 yr, range 13-96), 56.1% had PA. The systolic (164 29 vs. 155 27 mm...

10.1210/jc.2008-2116 article EN The Journal of Clinical Endocrinology & Metabolism 2009-02-04

In patients with primary aldosteronism, adrenal venous sampling is helpful to distinguish between unilateral and bilateral diseases. However, the procedure technically challenging, selective catheterization often fails. The aim of this analysis was evaluate success rate in a retrospective compare data procedures done prospectively after introduction measures designed improve rates successful cannulation. Patients were derived from cross-sectional study involving 5 German centers (German...

10.1161/hypertensionaha.110.168484 article EN Hypertension 2011-03-08
Coming Soon ...